Roche sees substantial synergies in Genentech deal

BASEL, Switzerland (Reuters) - Swiss drugmaker Roche Holding AG said on Monday it sees substantial synergies from the Genentech deal and that there would be no need for a capital increase.

The group said it was confident of putting together a consortium of banks to finance the $43.7 billion buy of all outstanding shares in its U.S. partner and that it sees no problems financing the deal.

(Reporting by Sam Cage)